2026 · Poster Presentation · Pharma Partner · Dermatology
94
Total Publications
38
Abstract/Manuscript
8
Oral Presentation
48
Poster Presentation
2026 · Poster Presentation · Keith Knapp · Dermatology
Healthcare Disparities in Hidradenitis Suppurativa in the US: TARGET-DERM HS.
Read more →2025 · Poster Presentation · Pharma Partner · Hepatology
Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry.
Read more →2025 · Poster Presentation · Pharma Partner · Dermatology
Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry.
Read more →2025 · Poster Presentation · Northwestern University · Dermatology
Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA.
Read more →2025 · Poster Presentation · Pharma Partner · Dermatology
Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA.
Read more →2025 · Poster Presentation · Yes · Methods/Pharmacoepi
Power Vs. Precision When Estimating Risk Differences Using Observational Data? A Case Study From TARGET-IBD.
Read more →2025 · Abstract/Manuscript · Yes
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH.
Read more →2025 · Abstract/Manuscript · Derek Gazis
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.
Read more →2025 · Abstract/Manuscript · Yes
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
Read more →2025 · Poster Presentation · Yes · Hepatology
Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease.
Read more →2025 · Poster Presentation · Yes · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort.
Read more →2025 · Poster Presentation · Pharma Partner · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions.
Read more →2025 · Poster Presentation · Derek Gazis · Hepatology
Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis.
Read more →2025 · Abstract/Manuscript · Atopic Dermatitis (AD)
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.
Read more →2025 · Abstract/Manuscript · Yes
Leveraging public health infrastructures to support sexual health for women living in the Southern United States.
Read more →2024 · Poster Presentation · Derek Gazis · Hepatology
Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status.
Read more →2024 · Poster Presentation · Yes · Hepatology
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups.
Read more →2024 · Poster Presentation · Yes · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score.
Read more →2024 · Poster Presentation · Derek Gazis · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH.
Read more →2024 · Poster Presentation · Yes · Hepatology
Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep Versus Adequate ALP Response to UDCA.
Read more →2024 · Poster Presentation · Medical University of South Carolina · Dermatology
Demographics and disease characteristics of patients with alopecia areata with comorbid atopic dermatitis, vitiligo or anxiety/depression: TARGET-DERM AA.
Read more →2024 · Poster Presentation · Atopic Dermatitis (AD) · Dermatology
Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from the TARGET-DERM AD Registry.
Read more →2024 · Poster Presentation · Keith Knapp · Dermatology
Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS.
Read more →2024 · Poster Presentation · Derek Gazis · Gastroenterology
Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort.
Read more →2024 · Poster Presentation · Keith Knapp · Gastroenterology
Time to Diagnosis Among Patients with Eosinophilic Esophagitis in the United States.
Read more →2024 · Poster Presentation · Pharma Partner · Methods/Pharmacoepi
Assessing The Value Of Linking Abstracted Medical Record Data With Administrative Claims Data To Study Patients With High-Risk Non-Muscle Invasive Bladder Cancer In The United States.
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort.
Read more →2024 · Abstract/Manuscript · Yes
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH.
Read more →2024 · Oral Presentation · Yes · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.
Read more →2024 · Oral Presentation · Keith Knapp · Dermatology
Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA.
Read more →2024 · Abstract/Manuscript · Yes
Use of tenofovir-based PrEP among pregnant women in South Africa.
Read more →2024 · Abstract/Manuscript · Yes
Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study.
Read more →2023 · Poster Presentation · Pharma Partner · Hepatology
NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US.
Read more →2023 · Poster Presentation · Yes · Hepatology
A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS.
Read more →2023 · Poster Presentation · Derek Gazis · Gastroenterology
Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD.
Read more →2023 · Poster Presentation · Derek Gazis · Gastroenterology
Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD.
Read more →2023 · Poster Presentation · Pharma Partner · Methods/Pharmacoepi
Analysis of discrimination and calibration of two cardiovascular risk scores in patients with non-alcoholic steatohepatitis shows a need for improved accuracy of these models.
Read more →2023 · Abstract/Manuscript · Yes
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Read more →2023 · Abstract/Manuscript · Pharma Partner
Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary.
Read more →2023 · Oral Presentation · Derek Gazis · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study.
Read more →2023 · Abstract/Manuscript · Atopic Dermatitis (AD)
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
Read more →2023 · Abstract/Manuscript · Atopic Dermatitis (AD)
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Read more →2023 · Abstract/Manuscript · Yes
Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease.
Read more →2023 · Abstract/Manuscript · Yes
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation.
Read more →2023 · Abstract/Manuscript · Yes
When Emulating a Trial, Do as the Trialists Do: Missteps in Estimating Relative Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster Dose.
Read more →2023 · Abstract/Manuscript · Yes
Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women.
Read more →2023 · Abstract/Manuscript · Yes
High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Read more →2023 · Oral Presentation · Yes · Methods/Pharmacoepi
HIV risk perception and PrEP adherence among South African women planning for pregnancy and participating in STI screening.
Read more →2022 · Poster Presentation · Yes · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH.
Read more →2022 · Poster Presentation · Pharma Partner · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks.
Read more →2022 · Poster Presentation · Pharma Partner · Gastroenterology
Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD.
Read more →2022 · Poster Presentation · Yes · Gastroenterology
Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis.
Read more →2022 · Poster Presentation · Yes · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19.
Read more →2022 · Poster Presentation · Morris H · Methods/Pharmacoepi
Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19.
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.
Read more →2022 · Abstract/Manuscript · Pharma Partner
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
Read more →2022 · Abstract/Manuscript · Atopic Dermatitis (AD)
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
Read more →2022 · Abstract/Manuscript · Yes
Postpartum Medicaid enrollment and churn in North Carolina.
Read more →2022 · Oral Presentation · Botswana Ministry of Health and Wellness · Methods/Pharmacoepi
HIV Incidence in Botswana Rural Communities With High Antiretroviral Treatment Coverage: Results From the Botswana Combination Prevention Project, 2013-2017.
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
Health Impact and Cost-Effectiveness of HIV Testing, Linkage, and Early Antiretroviral Treatment in the Botswana Combination Prevention Project.
Read more →2021 · Poster Presentation · Pharma Partner · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study.
Read more →2021 · Poster Presentation · Yes · Gastroenterology
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort.
Read more →2021 · Abstract/Manuscript · Pharma Partner
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis.
Read more →2021 · Abstract/Manuscript · Yes
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.
Read more →2021 · Abstract/Manuscript · Yes
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort.
Read more →2021 · Abstract/Manuscript · Yes
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Read more →2021 · Abstract/Manuscript · Yes
Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease.
Read more →2021 · Abstract/Manuscript · Yes
Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD.
Read more →2021 · Abstract/Manuscript · Pharma Partner
Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice.
Read more →2021 · Abstract/Manuscript · Yes
Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid From 2016 to 2018.
Read more →2021 · Abstract/Manuscript · Yes
Factors Associated with Readmission in the US Following Hospitalization with COVID-19.
Read more →2020 · Poster Presentation · Yes · Hepatology
A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes.
Read more →2020 · Poster Presentation · University of Birmingham (UK) · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice.
Read more →2020 · Poster Presentation · Yes · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study.
Read more →2020 · Poster Presentation · Pharma Partner · Gastroenterology
Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.
Read more →2020 · Oral Presentation · Yes · Hepatology
Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus.
Read more →2020 · Abstract/Manuscript · Pharma Partner
Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States.
Read more →2020 · Abstract/Manuscript · Levintow SN
Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines.
Read more →2020 · Abstract/Manuscript · Yes
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.
Read more →2020 · Oral Presentation · Yes · Gastroenterology
Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD.
Read more →2019 · Poster Presentation · Yes · Methods/Pharmacoepi
Factors Associated with Readmission Following COVID-19 Hospitalization.
Read more →2018 · Abstract/Manuscript · Yes
A Real-World Observational Cohort of Patients with Primary Biliary Cholangitis: TARGET-PBC Study Design and Rationale.
Read more →2018 · Abstract/Manuscript · Yes